Jamie Hoch, NP
Adult Health · Buffalo, NYNPI 1407545189
Payments from drug & device makers
Across 56 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$392
- Insulet Corporation$169
- Exact Sciences$92
- Pfizer$78
- Sanofi-aventis U.S. LLC$71
- Lilly USA, LLC$70
- plus $491 from 17 others
What the payments were for
- Food & beverage$1,32797%
- Education$363%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 9 | $392 |
| Insulet Corporation | 4 | $169 |
| Exact Sciences | 5 | $92 |
| Pfizer | 4 | $78 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Lilly USA, LLC | 4 | $70 |
| GSK | 4 | $59 |
| Novo Nordisk | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Kestra Medical Technology Services, Inc. | 1 | $44 |
| Medtronic | 2 | $36 |
| Vertex | 2 | $34 |
| Shield Therapeutics Inc | 2 | $27 |
| AstraZeneca | 1 | $27 |
| Gilead | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Indivior Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Cipher Pharmaceuticals US LLC | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,363 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 28 | $32,698 |
| OzempicSemaglutide | 30 | $29,138 |
| JanuviaSitagliptin Phosphate | 18 | $26,691 |
| FarxigaDapagliflozin Propanediol | 26 | $24,786 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,380 |
| JardianceEmpagliflozin | 11 | $15,151 |
| RybelsusSemaglutide | 11 | $10,025 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 182 | $5,056 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,354 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $3,180 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,129 |
| Atorvastatin Calcium | 198 | $1,725 |
| Omeprazole | 99 | $1,463 |
| Levothyroxine Sodium | 94 | $1,134 |
| Metoprolol Succinate | 62 | $1,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $48 | $39,16341 claims |
| Lilly USA, LLCTrulicity | $70 | $32,69828 claims |
| AstraZenecaFarxiga | $27 | $24,78626 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $59 | $23,73441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.
Other adult health in Buffalo
- Mary CiechoskiBuffalo$200K
- Rosemary HansenBuffalo$40K
- Susan DemarcoBuffalo$20K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.